SAWAI GROUP HOLDINGS Co.,Ltd.

4887 TSE Pharmaceuticals Pharmaceutical
TSE Prime
¥1,580.50
-1.53%
Delayed · cached 15 min

Fair value analysis

4887
SAWAI GROUP HOLDINGS Co.,Ltd.
PharmaceuticalsPharmaceutical
¥1,580.50
Close used for this calculation
¥1,554.98Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
43/100
Profitability6/25
Returns12/25
Balance Sheet7/25
Efficiency18/25
Growth5/25
Average
Quality radar
43Prof.6/25Ret.12/25Eff.18/25B.Sht7/25Growth5/25

Consensus fair value

¥1,554.98
Near FV
▼ -1.6% against the close used
Model range ¥611.94 – ¥1,807.80
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear¥611.94Fair value¥1,554.98Bull¥1,807.80
FairClose
52-week traded range
52W low ¥1,570.0052W high ¥2,425.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading close to the consensus fair value

SAWAI GROUP HOLDINGS Co.,Ltd. closed at ¥1,580.50, 1.6% above the consensus fair value of ¥1,554.98 drawn from 8 valuation models.

Financial DNA score 43/100 — Average. P/E of 17.5x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
¥1,694.14
+7.2%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
¥1,733.23
+9.7%
√(22.5 × EPS × BVPS)
EPS=90.39, BVPS=1477.1
P/E Fair Value
¥1,807.80
+14.4%
EPS × 20x (sector P/E)
EPS=90.39, Sector P/E=20x
EV/EBITDA
¥1,724.25
+9.1%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=31.9B
Dividend Discount (DDM)
¥701.27
-55.6%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=55, r=10%, g=2%
Book Value (P/B)
¥611.94
-61.3%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=1477.1, ROE=5.9%, g=3%, r=10%
Reverse DCF
¥1,580.50
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 5.3% | Historical: 0%
Margin of Safety
¥1,308.79
-17.2%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=1745.06, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.